Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.

Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.

In Vitro Diagnostics (IVD) Market To Reach USD 99.46 Billion By 2026 | Reports And Data Growth in the geriatric population and the widespread prevalence of chronic and infectious disease is fueling the market demand.  Market Size – USD 69.43 Billion in 2018, Market Growth - CAGR of...

Global Bioinformatics Market To Reach USD 18.96 Billion By 2026 | Reports And Data Rising need for integrated bioinformatics system in genomics and proteomics is fueling the growth of the market. Market Size – USD 6.41 Billion in 2018, Market Growth - CAGR of 13.2%, Market...